Journal for immunotherapy of cancer

Time of Day for Immunotherapy Infusion May Affect Survival and Immune Response in Patients with Advanced Kidney Cancer

Updated

Abstract

In a study of 201 patients with metastatic renal cell carcinoma, those who received 50% or more of their immune checkpoint inhibitor infusions before noon had a progression-free survival (PFS) hazard ratio of 0.67 and an overall survival (OS) hazard ratio of 0.57 compared to those who did not.

  • Patients receiving ICI infusions prior to noon demonstrated longer PFS and OS compared to those receiving infusions later in the day.
  • The median follow-up duration for participants was 18 months.
  • Half of the patients received at least 20% of their infusions before noon, while the other half received less.
  • Univariate and multivariable analyses indicated that earlier infusions are associated with improved survival outcomes.
  • These findings align with existing evidence suggesting that immune responses may be enhanced with earlier treatment times.

Simplified

Key numbers

0.67
PFS Hazard Ratio
Univariate analysis comparing Group A vs. Group B.
0.57
OS Hazard Ratio
Univariate analysis comparing Group A vs. Group B.
34%
Objective Response Rate Increase
Objective response rates for Group A vs. Group B.

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

Competing interests: None declared.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free